Journal article
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma
British journal of haematology, Vol.184(4), pp.524-535
02/2019
DOI: 10.1111/bjh.15720
PMCID: PMC6486816
PMID: 30575016
Abstract
Bendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma (FL) patients. The safety and efficacy of maintenance rituximab (MR) after BR induction has not been formally compared to observation for FL, resulting in disparate practice patterns. Prospective trials have shown benefit of MR after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or R-CVP (rituximab, cyclophosphamide, vincristine, prednisone), yet recent data from the GALLIUM study comparing outcomes of patients treated with chemotherapy with R or obinutuzumab (G) showed higher than anticipated fatal adverse events with BR/BG. In order to assess the efficacy and tolerability of MR after BR, we retrospectively collected data on 640 newly diagnosed patients treated with FL. We found that patients who achieved partial remission (PR) after ≥4 cycles of BR had improved duration of response (DOR) with MR vs. no maintenance, whereas those in complete remission did not. These findings were confirmed in a validation cohort. In the entire study population, the known fatal adverse event rate after BR was 2·5% and did not significantly differ in those receiving MR versus no maintenance. [Correction added on 14 January 2019, after online publication: The preceding sentence has been corrected in this current version.] Within the limitations inherent to retrospective analysis, these data suggest that FL patients with a PR to BR experience prolongation of remission with MR with an acceptable safety profile.
Details
- Title: Subtitle
- Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma
- Creators
- Brian T Hill - Cleveland ClinicLoretta Nastoupil - The University of Texas MD Anderson Cancer CenterAllison M Winter - Cleveland ClinicMelody R Becnel - The University of Texas MD Anderson Cancer CenterJames R Cerhan - Mayo ClinicThomas M Habermann - Mayo ClinicBrian K Link - University of Iowa Hospitals and ClinicsMatthew J Maurer - Mayo Clinic, Rochester, MN, USABita Fakhri - Washington University in St. LouisPrathima Reddy - Seattle Cancer Care AllianceStephen D Smith - Seattle Cancer Care AllianceDhruvika Mukhija - Cleveland ClinicDeepa Jagadeesh - Cleveland ClinicAmrita Desai - Sylvester Comprehensive Cancer CenterJuan Pablo Alderuccio - Sylvester Comprehensive Cancer CenterIzidore S Lossos - Sylvester Comprehensive Cancer CenterPooja Mehra - University of VirginiaCraig A Portell - University of VirginiaMax L Goldman - Emory UniversityOscar Calzada - Emory UniversityJonathon B Cohen - Emory UniversityMohammad J Hussain - Levine Cancer InstituteNilanjan Ghosh - Levine Cancer InstitutePaolo Caimi - University Hospitals of ClevelandTimothy Tiutan - Weill Cornell MedicinePeter Martin - Weill Cornell MedicineAbhigna Kodali - Tufts UniversityAndrew M Evens - Rutgers, The State University of New JerseyBrad S Kahl - Washington University in St. Louis
- Resource Type
- Journal article
- Publication Details
- British journal of haematology, Vol.184(4), pp.524-535
- DOI
- 10.1111/bjh.15720
- PMID
- 30575016
- PMCID
- PMC6486816
- ISSN
- 0007-1048
- eISSN
- 1365-2141
- Grant note
- U01 CA195568 / NCI NIH HHS P30 CA086862 / NCI NIH HHS P50 CA097274 / NCI NIH HHS
- Language
- English
- Date published
- 02/2019
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Internal Medicine
- Record Identifier
- 9984359663002771
Metrics
13 Record Views